The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth

serious or life-threatening disease or condition.5,7 It was initially formalized for the development of drugs to treat HIV infection; moreover, it continues to provide timely access to the treatment of cancers and other diseases.5 The accelerated in further study to "verify and describe clinical benefit, where there is uncertainty as to the relation of the surrogate endpoint to clinical benefit, or of the observed clinical benefit to the ultimate outcome."4-7 the practice of medicine, the medical services, the price or availability of medical products, and whether they are reimbursed by health insurance or Medicare.8 The FDA regulates the manufacturing of drugs and determines whether the scientific evidence is sufficient to allow marketing of the drug to the American public, and the FDA defines the labeling of the drug for the benefit and safety of the public.4,7-10